The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the launch of several new brands, including novel triptan and DHE reformulations and promising nontriptan NMEs. Among them are Eli Lilly’s Reyvow and two oral calcitonin gene-related peptide (CGRP) receptor antagonists—Allergan’s Ubrelvy and Biohaven’s Nurtec ODT—which together will drive strong growth in the large acute segment. However, it is the launch of four premium-priced anti-CGRP monoclonal antibodies and two oral gepants for episodic and chronic migraine prevention that will be the main driver of multi-billion-dollar sales growth of this market. These drugs follow in the footsteps of Allergan’s Botox (approved for chronic migraine), which has proven the commercial opportunity that new, valued brand alternatives can seize in the otherwise generic prophylaxis segment.
- How will Amgen / Novartis’s Aimovig, Teva’s Ajovy, Eli Lilly’s Emgality, and Lundbeck / Alder’s eptinezumab compete with one another and with established prophylactic therapies as their marketers vie for patient share? How will the launch of two oral CGRP receptor antagonists impact the migraine prophylaxis market?
- Will novel NMEs lasmiditan, ubrogepant, and rimegepant gain a foothold in the heavily generic acute segment dominated by triptans?
- How will new nonoral reformulations compete for patient share with existing brands and generics in the small niche patient population in need of nonoral alternatives?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Migraine - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Ruchita Kumar, Ph.D; Jonathan Searles; Shilpa Thakur
Ruchita has joined as a Lead Analyst in the Central Nervous System and Ophthalmology team at Decision Resources Group.
She comes with eight years of experience in handling various types of commercial assessment projects. She has worked on variety of opportunity assessment and market intelligence projects involving preparation of disease narratives, epi-based forecasts, patent landscapes, social media analysis and building brand performance reports across different therapy areas. She earned a Ph.D. in design and development of modified release dosage forms of anti-diabetic drugs from the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh.
Jonathan W. Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.
Shilpa Thakur is a medical graduate with a M.P.H from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics. She specializes in developing epidemiological forecasts for the multiple indications within the DRG syndicated portfolio.
Prior to joining Decision Resources, she monitored HIV sentinel surveillance 2016-2017 in Himachal Pradesh. She also has worked on to see the patterns of Antimicrobial resistance in India.